Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Sep;65(9):625-633.

Vaccine strategies for prevention of community-acquired pneumonia in Canada: Who would benefit most from pneumococcal immunization?

Alan Kaplan  1 , Pierre Arsenault  2 , Brian Aw  3 , Vivien Brown  4 , George Fox  5 , Ron Grossman  6 , Taj Jadavji  7 , Craig Laferrière  8 , Suzanne Levitz  9 , Mark Loeb  10 , Andrew McIvor  11 , Christopher H Mody  12 , Yannick Poulin  13 , Marla Shapiro  14 , Dominique Tessier  15 , Francois Théorêt  16 , Karl Weiss  17 , John Yaremko  18 , George Zhanel  19
Affiliations
Review

Vaccine strategies for prevention of community-acquired pneumonia in Canada: Who would benefit most from pneumococcal immunization?

Alan Kaplan et al. Can Fam Physician. 2019 Sep.

Abstract
in English, French

Objective: To describe the burden of pneumococcal disease and associated risk factors in the Canadian adult population, delineate available pneumococcal vaccines and associated efficacy and effectiveness data, and review current pneumococcal vaccine recommendations and community-acquired pneumonia (CAP) prevention strategies in Canada.

Quality of evidence: Pneumococcal vaccination guidelines from the Canadian National Advisory Committee on Immunization in 2013 and 2016 constitute level III evidence for CAP prevention in the Canadian adult population.

Main message: It is recommended that immunosuppressed adults of all ages receive the 13-valent pneumococcal conjugate vaccine (PCV13) (grades A and B recommendations). In 2016, the National Advisory Committee on Immunization also recommended that all adults aged 65 years and older receive PCV13 (grade A recommendation) on an individual basis, followed by the 23-valent pneumococcal polysaccharide vaccine (grade B recommendation). This update is based on a large clinical study that demonstrated PCV13 efficacy against vaccine-type CAP in this population.

Conclusion: Physicians should focus on improving pneumococcal vaccination rates among adults, which remain low. Vaccination with PCV13 should also be considered for adults with chronic conditions, whose baseline risk is often higher than that for healthy individuals aged 65 years and older.

Objectif: Décrire le fardeau des infections à pneumocoque et les facteurs de risque qui leur sont associés dans la population canadienne adulte, déterminer les vaccins disponibles contre le pneumocoque, cerner les données relatives à leur efficacité et à leur efficience réciproques, et examiner les recommandations actuelles sur le vaccin contre le pneumocoque, de même que les stratégies de prévention de la pneumonie d’origine communautaire (POC) au Canada.

Qualité des données: Les déclarations sur la vaccination contre le pneumocoque du Conseil consultatif national de l’immunisation du Canada en 2013 et en 2016 constituent une base de données probantes de niveau III pour la prévention de la POC dans la population adulte canadienne.

Message principal: Il est recommandé que les adultes en état d’immunodépression de tous les groupes d’âge reçoivent le vaccin conjugué 13-valent contre le pneumocoque (PCV13) (recommandations de grades A et B). En 2016, le Comité consultatif national de l’immunisation a aussi recommandé que tous les adultes de 65 ans et plus reçoivent le PCV13 (recommandation de grade A) sur une base individuelle, suivi du vaccin polysaccharidique 23-valent (recommandation de grade B). Cette mise à jour se fonde sur une étude clinique d’envergure qui a démontré l’efficacité dans cette population du PCV13 contre la POC due à un stéréotype contenu dans le vaccin.

Conclusion: Les médecins devraient aspirer à améliorer les taux de vaccination contre le pneumocoque chez les adultes, qui demeurent faibles. Le PCV13 devrait aussi être envisagé chez les adultes souffrant d’un problème chronique, dont le risque au départ est plus élevé que celui des personnes en santé de 65 ans et plus.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Pneumococcal vaccination guidelines for individuals aged ≥65 y PCV13—13-valent pneumococcal conjugate vaccine, PPSV23—23-valent pneumococcal polysaccharide vaccine. Data from the Public Health Agency of Canada and the National Advisory Committee on Immunization.,,
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. World Health Organization. The top 10 causes of death worldwide. Geneva, Switz: World Health Organization; 2018. Available from: www.who.int/mediacentre/factsheets/fs310/en/#. Accessed 2018 Oct 14.
    1. Statistics Canada. Leading causes of death, total population, by age group. All ages, both sexes. Ottawa, ON: Statistics Canada; 2018. Available from: www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/hlth36a-eng.htm. Accessed 2018 May 29.
    1. Marrie TJ, Huang JQ. Epidemiology of community-acquired pneumonia in Edmonton, Alberta: an emergency department-based study. Can Respir J. 2005;12(3):139–42. - PubMed
    1. McNeil S, Andrews M, Ye L, Elsherif M, MacKinnon-Cameron D, Ambrose A, et al. Active surveillance for community acquired pneumonia (CAP) amongst hospitalized Canadian adults, 2011–2013: a Public Health Agency of Canada/Canadian Institutes of Health Research (PCIRN) Serious Outcomes Surveillance (SOS) Network study. Poster 47.; Poster presented at: Canadian Immunization Conference; 2014 Dec 2–4; Ottawa, ON.
    1. Bergh C, Fall K, Udumyan R, Sjöqvist H, Fröbert O, Montgomery S. Severe infections and subsequent delayed cardiovascular disease. Eur J Prev Cardiol. 2017;24(18):1958–66. Epub 2017 Aug 1. - PubMed

MeSH terms

Substances